Compare MBUU & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBUU | PRTA |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 495.8M |
| IPO Year | 2014 | N/A |
| Metric | MBUU | PRTA |
|---|---|---|
| Price | $28.79 | $9.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $33.88 | $18.86 |
| AVG Volume (30 Days) | 215.8K | ★ 783.4K |
| Earning Date | 01-29-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $830,714,000.00 | $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.92 | $819.08 |
| P/E Ratio | $29.05 | ★ N/A |
| Revenue Growth | ★ 11.54 | N/A |
| 52 Week Low | $24.07 | $4.32 |
| 52 Week High | $42.49 | $16.67 |
| Indicator | MBUU | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 40.53 |
| Support Level | $28.85 | $9.23 |
| Resistance Level | $29.51 | $9.88 |
| Average True Range (ATR) | 0.84 | 0.46 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 0.22 | 16.78 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high end offshore and outboard motorboats in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.